Drug intelligence / Profile preview

Parasym Plus

Development stage: Unknown
Lead developer: TJ Nutrition
Modality: Small Molecules
Administration: Oral

Overview

Parasym Plus is an oral patented dietary supplement developed by TJ Nutrition to support vagus nerve function and the parasympathetic nervous system. It is marketed as a small-molecule nutraceutical capsule intended to increase acetylcholine availability and support acetylcholine receptor signaling, with promoted use in autonomic dysfunction and symptom complexes such as constipation, impaired bowel motility, brain fog, fatigue, inflammation, POTS, and CFS/ME. It is not an FDA-approved pharmaceutical product; rather, it is sold as a nutritional supplement composed of ingredients described as GRAS, and it has been associated with U.S. Patent No. 9,271,953 granted in May 2016 to Genetic Disease Investigators.

Brand names: Parasym Plus

Targets

AChR (Acetylcholine receptor)

Beyond the preview

Go deeper on Parasym Plus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Parasym Plus.

Explore the full profile